Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEONNASDAQ:ATNXNASDAQ:KTTANASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.89-7.7%$0.53$0.38▼$269.28$10.08M0.571.02 million shs476,102 shsATNXAthenex$0.95$0.20▼$23.80$1.76M1.36194,316 shs1.88 million shsKTTAPasithea Therapeutics$0.83-2.3%$1.16$0.79▼$7.50$6.17M0.332.07 million shs157,143 shsMYNZMainz Biomed$1.99-2.5%$2.65$1.92▼$28.00$6.85M0.31131,313 shs59,796 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma+2.80%+47.64%+96.40%+60.78%-99.09%ATNXAthenex0.00%0.00%0.00%0.00%0.00%KTTAPasithea Therapeutics-3.65%-6.91%-2.41%-18.37%-84.76%MYNZMainz Biomed-1.92%0.00%-19.69%-56.87%-92.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEONAEON Biopharma2.6954 of 5 stars3.52.00.00.01.11.71.9ATNXAthenex0.1324 of 5 stars0.00.00.04.10.00.00.0KTTAPasithea Therapeutics1.6397 of 5 stars0.05.00.00.02.81.70.6MYNZMainz Biomed2.8339 of 5 stars3.35.00.00.01.40.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0040,263.27% UpsideATNXAthenex 0.00N/AN/AN/AKTTAPasithea Therapeutics 0.00N/AN/AN/AMYNZMainz Biomed 2.50Moderate Buy$14.00603.52% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AATNXAthenex$102.82M0.00N/AN/A($3.07) per share0.00KTTAPasithea TherapeuticsN/AN/AN/AN/A$22.46 per shareN/AMYNZMainz Biomed$893.99K7.66N/AN/A$10.82 per share0.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M$298.124.96N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)ATNXAthenex-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/AKTTAPasithea Therapeutics-$15.96M-$10.60N/A∞N/AN/A-81.57%-74.31%8/11/2025 (Estimated)MYNZMainz Biomed-$26.30M-$65.60N/AN/AN/AN/AN/AN/A7/1/2025 (Estimated)Latest ATNX, KTTA, MYNZ, and AEON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/1/2025N/AMYNZMainz Biomed-$2.80N/AN/AN/AN/AN/A5/15/2025Q1 2025KTTAPasithea TherapeuticsN/A-$1.61N/A-$1.61N/AN/A3/24/2025Q4 2024KTTAPasithea TherapeuticsN/A-$2.41N/A-$2.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/AATNXAthenexN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22ATNXAthenex3.081.090.72KTTAPasithea TherapeuticsN/A14.8214.82MYNZMainz BiomedN/A0.240.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%ATNXAthenex30.48%KTTAPasithea Therapeutics23.92%MYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%ATNXAthenex9.20%KTTAPasithea Therapeutics16.30%MYNZMainz Biomed18.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.31 million74.37 millionNot OptionableATNXAthenex6528.66 million7.87 millionOptionableKTTAPasithea Therapeutics37.44 million1.06 millionNot OptionableMYNZMainz Biomed303.44 million1.64 millionNot OptionableATNX, KTTA, MYNZ, and AEON HeadlinesRecent News About These CompaniesPromising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy RatingJune 11 at 2:27 PM | tipranks.comMainz BioMed NV: Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10 at 11:12 AM | finanznachrichten.deMainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von BauchspeicheldrüsenkrebsJune 10 at 11:12 AM | anlegerplus.deMainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10 at 11:12 AM | finance.yahoo.comMainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert ProjectJune 10 at 10:01 AM | quiverquant.comMainz Biomed N.V. Shareholders Approve Key Proposals at Annual MeetingJune 5, 2025 | tipranks.comMainz Biomed N.V. Secures $4 Million Through Securities OfferingMay 21, 2025 | tipranks.comMainz Biomed prices $4M securities offeringMay 20, 2025 | seekingalpha.comMainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and WarrantsMay 19, 2025 | investing.comMainz Biomed Announces Pricing of $4 Million Follow-On Offering and Warrant AmendmentsMay 19, 2025 | quiverquant.comMainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and WarrantsMay 19, 2025 | globenewswire.comMainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekanntMay 16, 2025 | anlegerplus.deMainz Biomed wird bis Ende Sommer Update zur Darmkrebs-Screening-Studie gebenMay 16, 2025 | de.investing.comEQS-News: Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekanntMay 16, 2025 | onvista.deMainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical StudyMay 16, 2025 | globenewswire.comMainz Biomed launches public offering of units and warrantsMay 16, 2025 | msn.comMainz Biomed kündigt Jahreshauptversammlung für den 2. Juni anMay 2, 2025 | de.investing.comMainz Biomed Prepares for June 2025 Annual General MeetingMay 2, 2025 | tipranks.comMainz Biomed gibt Technologiepartnerschaft mit EDX Medical Group bekanntApril 29, 2025 | anlegerplus.deMainz Biomed advances in FDA approval for CRC testApril 29, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATNX, KTTA, MYNZ, and AEON Company DescriptionsAEON Biopharma NASDAQ:AEON$0.89 -0.07 (-7.70%) As of 04:00 PM EasternAEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Athenex NASDAQ:ATNXAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Pasithea Therapeutics NASDAQ:KTTA$0.83 -0.02 (-2.33%) As of 04:00 PM EasternPasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Mainz Biomed NASDAQ:MYNZ$1.99 -0.05 (-2.45%) As of 03:59 PM EasternMainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
